Research Groups and R&D Platforms: Hit to lead
Research Group:
Medicinal Chemistry
Olli Pentikäinen
olli.pentikainen[at]utu.fi
Institute of Biomedicine,
University of Turku
Autoimmune diseases, Basic research, Bioinformatics, Biomedicine, Cancer, Hit to lead, Inflammation, Inherited diseases, Lead optimization, Medicinal chemistry, Molecular modelling, Organic compounds, Pharmacology, Physico-chemical properties, Receptor, Screening, Signaling, Structural Biology, Synthetic chemistry
Research Group:
Systems Molecular Engineering
Jianwei Li
jianwei.li[at]utu.fi
Department of Chemistry,
University of Turku
Atomic-force microscopy, Basic research, Biochemistry, Biomarker, Biomedicine, Biomolecular chemistry, Biotechnology, Cancer, Chemical Physics, Combinatorial chemistry, Drug delivery, Drug target, Electron microscopy, Fluorescence spectroscopy, FTIR or RAMAN spectroscopy, Hit to lead, Imaging, Infection, Inflammation, Lead optimization, Medicinal chemistry, Microstructure analysis, Molecular modelling, Nanoparticles, Natural Compounds, Next-generation sequencing, NMR, Nucleic acids, Organic Chemistry, Organic compounds, Particle size analysis, Physico-chemical properties, Powder X-ray diffraction, Preclinical development, Proteomics, Screening, Structural Biology, Synthetic Biology, Synthetic chemistry, Thermal analysis, X-ray crystallography
Research Group:
Structural bioinformatics for drug discovery and development
Mark S. Johnson
finmark54 at icloud dot com
Biochemistry,
Åbo Akademi University
Structural Bioinformatics Laboratory
Ageing-related diseases, Autoimmune diseases, Basic research, Biochemistry, Bioinformatics, Biomolecular chemistry, Biopharmaceuticals, Biotechnology, Cancer, Chemical Physics, Computer Science, Diabetes, Drug target, Hit to lead, Inflammation, Inherited diseases, Lead optimization, Lung cancer, Medicinal chemistry, Metabolic diseases, Molecular modelling, Musculoskeletal disorders, Nucleic acids, Organic compounds, Pattern recognition, Personalized medicine, Physico-chemical properties, Preclinical development, Receptor, Signaling, Structural Biology, Surface area, Target discovery, X-ray crystallography
Research Group:
Bio-Organic Chemistry
Tuomas Lönnberg
tuanlo[at]utu.fi
Department of Chemistry,
University of Turku
Basic research, Biomolecular chemistry, Diagnostics, Fluorescence spectroscopy, Hit to lead, In Vitro Diagnostics, Lead optimization, NMR, Nucleic acids, Organic Chemistry, Organic compounds, Synthetic chemistry
R&D Platform:
Screening Unit
The screening unit offers academic researchers and industrial customers a broad range of services for identifying and optimising bioactive molecules for the drug discovery process. These include molecular modelling and in silico screening, development of screening assays and compound library screens, in vitro and in situ hit validation, hit optimisation and SAR analyses. A suite of cell and tissue-based disease models for oncology and neurological diseases are available for further validation of optimised hits or for independent phenotypic screens. High-throughput kinetic assays of changes in morphology or intracellular signalling over time may be integrated into chemical, genetic or optogenetic perturbation screens. A library of reporters in gene-delivery vectors are available for this purpose. The unit also has experience performing screens and toxicological evaluations in small animal models.
Contact details
High-throughput screens, screen-compatible assays, high-throughput microscopy, libraries, optogenetics, cell-based neurological disease models:
michael.courtney[at]utu.fi
3D oncology models, phenotypic screens, high-content screens:
malin.akerfelt[at]utu.fi
Medicinal chemistry, virtual screening and molecular modelling:
olli.pentikainen[at]utu.fi
Assay development, Basic research, Disease models, High throughput imaging, Hit to lead, Lead optimization, Medicinal chemistry, Molecular modelling, R&D Platforms, Screening, Signaling, Target discovery
Research Group:
Recombinant antibodies and other bioaffinity molecules
Urpo Lamminmäki
urplammi[at]utu.fi
Department of Life Technologies,
University of Turku
Antibodies, Assay development, Basic research, Biomarker, Biotechnology, Cancer, Combinatorial chemistry, Diagnostics, Drug target, Fluorescence spectroscopy, Hit to lead, In Vitro Diagnostics, Infection, Lead optimization, Metabolic diseases, Molecular Biology, Molecular modelling, Nanoparticles, Next-generation sequencing, Ovarian cancer, Point of care, Prostate cancer, Screening, Synthetic Biology, Target discovery
